🍊Our missionGreat science regularly stalls in the clinic, not because the science is wrong, but because the company behind it lacks the capital, infrastructure, or focus to take it all the way through.
Today’s clinical-stage biopharma model is broken, and as a result promising treatments never reach patients.
Our mission is to fix this: we’re building the next generation of biopharma by in-licensing clinical-stage therapeutic assets and developing them through Lindus Health’s integrated, technology-first clinical trial infrastructure.
We’re a new initiative, but we’re building on a proven foundation - the same infrastructure that has delivered 82% of Lindus Health’s sponsor trials on or ahead of timeline, across 40+ completed trials across the US and Europe.
We’re in-licensing 5-7 clinical-stage, typically Phase-2-ready assets, funded directly from Lindus Health’s balance sheet.
We’re targeting deal close on our first assets through 2026, with first trials launching in H1 2027.
It's a genuine coach-player role - as much applied biostatistician as director.
This seat carries real weight: the statistical rigour of an incoming asset's data package shapes deal terms and development risk, and it's Lindus Therapeutics' primary statistical voice with regulators.
You'll work closely with clinical, medical, data architecture, and business development colleagues, and build out the wider biostatistics function as the portfolio grows.
🍊 About youWe'd like to hear from you if…PhD in statistics or biostatistics with 10+ years' relevant pharma/biotech experience, or MS with 15+ years, including lead statistician experience across multiple Phase I/II programmes (Phase III and CSR experience a plus)Personall.